HONG KONG – Not only are South Korean biotech companies working their way into the global biosimilars market, they are also tapping the market for gene-based medicines and taking a global leadership role.
HONG KONG – Not only are South Korean biotech companies working their way into the global biosimilars market, they are also tapping the market for gene-based medicines and taking a global leadership role.
HONG KONG – China’s economy may be slowing down, but multinationals are positioning themselves to leverage it as best they can while navigating a still-complex regulatory environment. The latest: Pfizer Inc. last week broke ground on a $350 million biotechnology facility in eastern Hangzhou. The Global Biotechnology Center will be Pfizer’s first biotech center in Asia and its third globally.
HONG KONG – China's economy may be slowing down, but multinationals are positioning themselves to leverage it as best they can while navigating a still-complex regulatory environment. The latest: Pfizer Inc. this week broke ground on a $350 million biotechnology facility in eastern Hangzhou. The Global Biotechnology Center will be Pfizer's first biotech center in Asia and its third globally.
